NERV - Minerva Neurosciences, Inc.
7.3
-0.640 -8.767%
Share volume: 213,046
Last Updated: 03-11-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.16%
PREVIOUS CLOSE
CHG
CHG%
$7.94
-0.64
-0.08%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-01-2024 | 08-06-2024 | 11-05-2024 | 02-25-2025 | 05-13-2025 | 08-14-2025 | 11-05-2025 | |
| Assets | ||||||||
| Total Assets | 50.510 M | 46.291 M | 42.812 M | 37.144 M | 32.798 M | 30.420 M | 28.092 M | |
| Current Assets | 35.621 M | 31.409 M | 27.936 M | 22.269 M | 17.925 M | 15.548 M | 13.020 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 34.818 M | 30.881 M | 26.529 M | 21.362 M | 17.290 M | 15.248 M | 12.287 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 9.524 K | 8.163 K | 6.802 K | 5.442 K | 4.081 K | 2.721 K | 1.360 K | |
| Other Assets | 14.880 M | 14.874 M | 14.869 M | 14.869 M | 14.869 M | 14.869 M | 15.071 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 50.510 M | 46.291 M | 42.812 M | 37.144 M | 32.798 M | 30.420 M | 28.092 M | |
| Total liabilities | 87.098 M | 90.782 M | 64.483 M | 62.837 M | 61.947 M | 62.529 M | 62.672 M | |
| Total current liabilities | 2.831 M | 4.203 M | 4.483 M | 2.837 M | 1.947 M | 2.529 M | 2.672 M | |
| Accounts Payable | 2.831 M | 4.203 M | 4.483 M | 2.837 M | 1.947 M | 2.529 M | 2.672 M | |
| Other liabilities | 84.267 M | 86.579 M | 60.000 M | 60.000 M | 60.000 M | 60.000 M | 60.000 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 84.267 M | 86.579 M | 60.000 M | 60.000 M | 60.000 M | 60.000 M | 60.000 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | -36.587 M | -44.492 M | -21.671 M | -25.693 M | -29.149 M | -32.109 M | -34.580 M | |
| Common stock | 368.797 M | 369.126 M | 369.434 M | 369.683 M | 369.981 M | 370.279 M | 370.552 M | |
| Retained earnings | -405.384 M | -413.618 M | -391.105 M | -395.377 M | -399.130 M | -402.388 M | -405.132 M |